enGene Therapeutics (ENGN) Operating Expenses (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Operating Expenses of $32.0 million for Q2 2026, up 17.86% year-over-year from $27.1 million in Q2 2025, and up 2.51% quarter-over-quarter from $31.2 million in Q1 2026.
enGene Therapeutics (ENGN) Operating Expenses (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Operating Expenses for 4 consecutive years, with $32.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Expenses rose 17.86% year-over-year to $32.0 million; the TTM figure through Apr 2026 stood at $132.6 million (up 3057.44% YoY), while the FY2025 annual figure was $123.2 million, up 1621.38% from the prior year.
- Operating Expenses grew to $32.0 million in Q2 2026 per ENGN's latest filing, from $31.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $39.5 million in Q4 2025 and bottomed at -$37.7 million in Q4 2024.
- Historically, Operating Expenses has averaged $13.6 million across 4 years, with a median of $13.8 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Expenses sank 460.92% — and 2026, when it soared 1661.59%.
- enGene Therapeutics' Operating Expenses stood at $10.4 million in 2023, then tumbled by 460.92% to -$37.7 million in 2024, then soared by 204.76% to $39.5 million in 2025, then retreated by 19.03% to $32.0 million in 2026.
- Business Quant data shows ENGN's Operating Expenses at $32.0 million in Q2 2026, $31.2 million in Q1 2026, and $39.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 541.02 Mn |
| 10 | enGene Therapeutics | 124.46 Mn | 124.46 Mn | - | 31.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 31.97 Mn |
| Jan 31, 2026 | 31.19 Mn |
| Oct 31, 2025 | 39.48 Mn |
| Jul 31, 2025 | 29.95 Mn |
| Apr 30, 2025 | 27.12 Mn |
| Jan 31, 2025 | -2.00 Mn |
| Oct 31, 2024 | -37.69 Mn |
| Jul 31, 2024 | 16.76 Mn |
| Apr 30, 2024 | 17.31 Mn |
| Jan 31, 2024 | 10.77 Mn |
| Oct 31, 2023 | 10.44 Mn |
| Jul 31, 2023 | 6.25 Mn |
| Apr 30, 2023 | 4.74 Mn |
| Jan 31, 2023 | 4.63 Mn |